

Supplementary Material

Antifungal activity of Co(II) and Cu(II) complexes containing 1,3-bis(benzotriazol-1-yl)-propan-2-ol on the growth and virulence traits of fluconazole-resistant *Candida* species: Synthesis, DFT calculations, and biological activity

Ricardo A. Murcia-Galan¹, Sandra M. Durán², Sandra M. Leal-Pinto², Martha V. Roa-Cordero², Jose D. Vargas², Laura V. Herrera³, Alvaro Muñoz-Castro⁴, Desmond MacLeod-Carey⁵, Tonny W. Naranjo^{6,7}, Peter L. Rodríguez-Kessler,⁸ John J. Hurtado^{1*}

¹Grupo de investigación en Química Inorgánica, Catálisis y Bioinorgánica, Departamento de Química, Universidad de los Andes, Carrera 1 No. 18A-12, 111711, Bogotá-Colombia; ra.murcia@uniandes.edu.co; jj.hurtado@uniandes.edu.co

²Universidad de Santander, Facultad de Ciencias Médicas y de la Salud, Calle 70 No. 55-210, Bucaramanga-Colombia; sandramduranbarajas@gmail.com sa.leal@mail.udes.edu.co; ma.roa@mail.udes.edu.co; vargasjosedavid.7.3@gmail.com

³Grupo Sistema Estomatognático y Morfofisiología (SEMF). Departamento de Ciencias Básicas, Universidad Santo Tomás seccional Bucaramanga, cra 27 No. 180-395, Bucaramanga-Colombia; laura.herrera01@ustabuca.edu.co

⁴Facultad de Ingeniería, Arquitectura y Diseño, Universidad San Sebastián, Bellavista 7, Santiago, 8420524 Chile; alvaro.munozc@uss.cl

⁵Universidad Autónoma de Chile, Facultad de Ingeniería, Instituto de Ciencias Químicas Aplicadas, Inorganic Chemistry and Molecular Materials Center, El Llano Subercaseaux 2801, Santiago, Chile; desmond.macleod@uautonoma.cl

⁶ Corporación para Investigaciones Biológicas (CIB), Experimental and Medical Micology Group, Medellín 050010, Colombia; tnaranjo@cib.org.co

⁷ Universidad Pontificia Bolivariana, Facultad de Medicina, Medellín 050034, Colombia; tnaranjo@cib.org.co

⁸Centro de Investigaciones en Óptica A.C., Loma del Bosque 115, Col. Lomas del Campestre, León, Guanajuato, 37150, México; plkessler@cio.mx

* Correspondence: jj.hurtado@uniandes.edu.co; Tel.: +57-1-3394949 (ext. 3468), ORCID: <https://orcid.org/0000-0002-0511-9719>




Figure S1. ^1H NMR spectrum of 1,3-bis(benzotriazole-1-yl)propan-2-ol (**1**) in DMSO-d_6




Figure S2. ^{13}C NMR spectrum of 1,3-bis(benzotriazole-1-yl)propan-2-ol (**1**) in DMSO-d_6




Figure S3. DEPT NMR spectrum of 1,3-bis(benzotriazole-1-yl)propan-2-ol (**1**) in DMSO-d₆




Figure S4. HSQC NMR spectrum of 1,3-bis(benzotriazole-1-yl)propan-2-ol (**1**) in DMSO-d₆




Figure S5. MS spectrum of 1,3-bis(benzotriazole-1-yl)propan-2-ol (**1**)




Figure S6. FT-IR (ATR) spectrum of 1,3-bis(benzotriazole-1-yl)propan-2-ol (**1**)




Figure S7. FT-IR (ATR) spectrum of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (**2**)




Figure S8. FT-IR (ATR) spectrum of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) (**3**)




Figure S9. FT-IR (ATR) spectrum of diacetate-diaqua-[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (**4**)




Figure S10. FT-IR (ATR) spectrum of diacetate[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) dihydrated (**5**)




Figure S11. Raman spectrum of 1,3-bis(benzotriazole-1-yl)propan-2-ol (**1**)




Figure S12. Raman spectrum of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (2)




Figure S13. Raman spectrum of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) (3)




Figure S14. Raman spectrum of diacetate-diaqua-[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (4)




Figure S15. Raman spectrum of diacetate[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) dihydrated (5)




Figure S16. Thermogravimetric (TG) analysis and derivative thermogravimetric (DTG) of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (**2**) in nitrogen atmosphere




Figure S17. Thermogravimetric (TG) analysis and derivative thermogravimetric (DTG) of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) (**3**) in nitrogen atmosphere




Figure S18. Thermogravimetric (TG) analysis and derivative thermogravimetric (DTG) of diacetate-diaqua-[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (4) in nitrogen atmosphere




Figure S19. Thermogravimetric (TG) analysis and derivative thermogravimetric (DTG) of diacetate[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) dihydrated (5) in nitrogen atmosphere




Figure S20. UV-Vis spectrum of 1,3-bis(benzotriazole-1-yl)propan-2-ol (**1**) in methanol. 2.10×10^{-5} M, 200-1000 nm region




Figure S21. UV-Vis spectrum of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (**2**) in methanol. 2.18×10^{-5} M, 200-1000 nm region




Figure S22. UV-Vis spectrum of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (**2**) in methanol. 4.72×10^{-3} M, 400-700 nm region




Figure S23. UV-Vis spectrum of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) (**3**) in methanol. 2.16×10^{-5} M, 200-1000 nm region




Figure S24. UV-Vis spectrum of dichloro[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) (**3**) in methanol. 4.66×10^{-3} M, 400-1000 nm region




Figure S25. UV-Vis spectrum of diacetate-diaqua-[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (**4**) in methanol. 1.82×10^{-5} M, 200-1000 nm region




Figure S26. UV-Vis spectrum of diacetate-diaqua-[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']cobalt(II) (**4**) in methanol. 3.94×10^{-3} M, 400-700 nm region




Figure S27. UV-Vis spectrum of diacetate[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) dihydrated (**5**) in methanol. 1.81×10^{-5} M, 200-1000 nm region




Figure S28. UV-Vis spectrum of diacetate[1,3-bis(benzotriazole-1-yl)propan-2-ol-N,N']copper(II) dihydrated (**5**) in methanol. 3.91×10^{-3} M, 400-1000 nm region




Figure S29. Optimized geometry of conformer Da of (2) – Different perspectives




Figure S30. Optimized geometry of conformer Db of (2) – Different perspectives




Figure S31. Optimized geometry of conformer Dc of (2) – Different perspectives




Figure S32. Optimized geometry of conformer Dd of (2) – Different perspectives




Figure S33. Optimized geometry of conformer Qa of (2) – Different perspectives




Figure S34. Optimized geometry of conformer Qb of (2) – Different perspectives




Figure S35. Optimized geometry of conformer Qc of (2) – Different perspectives




Figure S36. Optimized geometry of conformer Qd of (2) – Different perspectives




Figure S37. Optimized geometry of conformer Da of (3) – Different perspectives




Figure S38. Optimized geometry of conformer Db of (3) – Different perspectives




Figure S39. Optimized geometry of conformer Dc of (3) – Different perspectives




Figure S40. Optimized geometry of conformer Dd of (3) – Different perspectives




Figure S41. Drug interaction isobolograms. A: A (Caspofungin vs Complex 4 against *C. tropicalis* 66029) B (Fluconazole vs Complex 4 *C. albicans* 90028).




Figure S42. Synthesis of the ligand (1). TBAB = Tetrabutylammonium bromide

Table S1. Thermoanalytical results (TGA and DTG) for metal complexes.

Compound (formula)	TG range / °C	DTG _{max} / °C		Total		Assignment	Metallic residue
				Mass loss	mass loss		
				Estimated (calcd.) / %			
2 (C ₁₅ H ₁₄ Cl ₂ CoN ₆ O)	152-352	254, 337	2	31.63 (31.63)		loss of C ₆ H ₄ N ₃ + CH ₄	CoCl ₂ CO
	352-385	365	1	9.52 (9.45)	63.55	loss of C ₃ H ₄	
	385-473	421	1	12.53 (12.74)	(62.78)	loss of CN ₃	
	473-694	512	1	9.86 (8.97)		loss of C ₃ H ₂	
3 (C ₁₅ H ₁₄ Cl ₂ CuN ₆ O)	27-170	46, 148	2	1.99 (1.88)		loss of 4H ₂	CuCl
	170-253	236	1	9.25 (9.11)	76.79	loss of C ₃ H ₃	
	253-552	321	1	62.14 (62.41)	(76.91)	loss of C ₁₁ N ₆ ClO	
4 (C ₁₉ H ₂₄ CoN ₆ O ₇)	552-694	694	1	3.40 (3.50)		loss of CH ₃	CoC ₂ O ₄
	27-239	88, 159, 202	3	9.38 (9.47)		loss of 2H ₂ O + C	
	239-358	294	1	34.10 (34.13)	71.82	loss of C ₆ H ₄ N ₃ + C ₃ H ₃ O	
	358-573	420, 495	2	22.81 (22.88)	(71.04)	loss of C ₆ H ₂ N ₃	
5 (C ₁₉ H ₂₄ CuN ₆ O ₇)	573-694	676	1	5.52 (4.55)		loss of CH ₃ + 4H ₂	CuC ₂ O ₄
	64-126	95	1	7.54 (7.43)		loss of 2H ₂ O + H ₂	
	126-239	170, 207	2	25.35 (25.42)	70.06	loss of C ₆ H ₄ N ₃ + C	
	239-357	296	1	28.37 (28.55)	(70.40)	loss of C ₆ H ₄ N ₃ + C ₂ H ₄	
	357-694	405	1	8.80 (8.99)		loss of C ₂ H ₆ O	

Table S3. Matrix of combinations between cobalt(II) complexes and reference drugs (FCZ and Caspofungin).

Combination	Drug A (Complexes)	Drug B (Reference drugs)
1	8X MIC	0
2	4X MIC	1/4 MIC
3	2X MIC	1/2 MIC
4	MIC	MIC
5	1/2 MIC	2X MIC
6	1/4 MIC	4X MIC
7	0	8X MIC